| Literature DB >> 29209259 |
Manuela Schuetze1,2,3,4, Christiane S Rohr1,2,5, Deborah Dewey2,6,7, Adam McCrimmon2,8, Signe Bray1,2,4,5,7.
Abstract
Early behavioral interventions are recognized as integral to standard care in autism spectrum disorder (ASD), and often focus on reinforcing desired behaviors (e.g., eye contact) and reducing the presence of atypical behaviors (e.g., echoing others' phrases). However, efficacy of these programs is mixed. Reinforcement learning relies on neurocircuitry that has been reported to be atypical in ASD: prefrontal-sub-cortical circuits, amygdala, brainstem, and cerebellum. Thus, early behavioral interventions rely on neurocircuitry that may function atypically in at least a subset of individuals with ASD. Recent work has investigated physiological, behavioral, and neural responses to reinforcers to uncover differences in motivation and learning in ASD. We will synthesize this work to identify promising avenues for future research that ultimately can be used to enhance the efficacy of early intervention.Entities:
Keywords: autism spectrum disorder; conditioning; neuroimaging; reinforcement learning; reward
Year: 2017 PMID: 29209259 PMCID: PMC5702301 DOI: 10.3389/fpsyg.2017.02035
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Participant characteristics of reviewed ASD studies in section Physiological, Behavioral, and Neural Responses to Reinforcers in ASD.
| Anderson et al., | 9 (8) | 9 (8) | 7 AD and 2 PDD-NOS | ADOS-G | 4.1 | 4.1 | NA | NA | NA | NA | NA | NA |
| Blair, | 20 (16) | 20 (12) | Autism | IC | 11.95 (2.81) | 6.27 (0.43) | NA | NA | 58.8 (11.3) | NA | NA | NA |
| Cascio et al., | 19 (19) | 18 (18) | ASD (no psychotropic medication or abstained from stimulants for 24 h) | ADOS and ADI-R | 12.58 (2.48) | 13.11 (3.44) | 109.52 (13.96) | 104.22 (12.45) | NA | NA | NA | NA |
| Cattaneo et al., | 7 (6) | 8 (4) | HFA | ADOS and ADI-R | 6.2 | 6.5 | 98 | 104.6 | NA | NA | NA | NA |
| Cattaneo et al., | 8 (7) | 8 (4) | HFA | ADOS and ADI-R | 6.2 | 6.5 | 98 | 104.7 | NA | NA | NA | NA |
| Damiano et al., | 20 (17) | 38 (34) | 12 HFA, 8 AS | ADOS-G | 25.9 (7.96) | 20.4 (5.64) | 114.7 (11.2) | 112.8 (8.6) | 112.5 (14.6) | 112.9 (9.9) | 113.6 (10.3) | 109.1 (9.0) |
| Damiano et al., | 24 (23) | 21 (17) | ASD (13 with psychotropic medication) | ADOS | 14.35 (3.16) | 14.25 (2.98) | 106.9 (16.3) | 110.7 (13.5) | 105.7 (17.9) | 110.1 (14.2) | 106 (15.4) | 108.4 (12.0) |
| Dichter et al., | 20 (17) | 37 (33) | 8 AD, 7 AS, 3 PDD-NOS, 2 not specified (8 with psychotropic medication) | ADI-R | 12.4 (1.8) | 17.4 (4.8) | NA | NA | NA | NA | NA | NA |
| Dichter et al., | 16 (14) | 20 (14) | 2 AS, 14 HFA (9 with psychotropic medication) | ADOS-G | 26 (9.1) | 25.3 (7) | 109.9 (20.3) | 127 (8.1) | 108.1 (24) | 125.6 (9.5) | 109.1 (14.1) | 122.2 (7.5) |
| Dubey et al., | 30 (21) | 24 (14) | ASD | IC or ADOS | 20-60 | 20-60 | 115.8 | 118 | 117.8 | 117.8 | 110.1 | 114.8 |
| Ewing et al., | 19 (17) | 19 (17) | 15 AD, 3 AS, 1 PPD-NOS | ADOS-G | 11.3 (2.24) | 11.4 (2.7) | NA | NA | 100 (12.2) | 101.3 (8.8) | 98.2 (14.3) | 96.8 (7.6) |
| Hanley et al., | 14 (NA) | 14 (NA) | AS | ADI-R | 20.6 | 20.4 | NA | NA | NA | NA | NA | NA |
| Hubert et al., | 16 (14) | 16 (14) | HFA or AS | Autism Spectrum Screening Questionnaire | 25.6 (9.2) | 27.2 (10.6) | 92.2 | NA | NA | NA | NA | NA |
| Joseph et al., | 20 (18) | 20 (13) | Autism or PDD-NOS | ADOS or ADI-R | 12.6 (2.0) | 11.11 (1.9) | NA | NA | 98 (20) | 102 (16) | NA | NA |
| Klin et al., | 15 (15) | 15 (15) | AD | ADOS | 15.4 (7.2) | 17.9 (5.6) | NA | NA | 101.3 (24.9) | 102.5 (20.4) | NA | NA |
| Kohls et al., | 15 (15) | 17 (17) | AS (no psychotropic medication) | ADOS and ADI-R | 14.6 (3.3) | 13.9 (3.0) | 109.8 (12.1) | 112.9 (12.6) | NA | NA | NA | NA |
| Lin et al., | 10 (7) | 10 (7) | Autism or AS | ADOS and ADI-R | 28 (3.1) | 27 (3.1) | 113 (4.7) | 114 (13.4) | NA | NA | NA | NA |
| Mathersul et al., | 18 (14) | 18 (13) | HFA | AQ and/or Ritvo Autism Asperger's Diagnostic Scale | 44.6 (15.5) | 36.7 (17.1) | 117.4 | NA | 114.4 | NA | 115.8 | NA |
| Oberman et al., | 13 (13) | 13 (13) | 13 AD, 6 ASD | ADOS-G | 10.2 (1.4) | 10.2 (1.4) | 102.8 (15.8) | 112.5 (17.3) | NA | NA | NA | NA |
| Pierce et al., | 37 (30) | 51 (16) | 27 AD, 9 PDD-NOS, 1 ASD features | ADOS-Toddler Module | 2.2 (0.64) | 1.89 (0.71) | NA | NA | NA | NA | NA | NA |
| Riby and Hancock, | 20 (15) | 20 (14) | Autism | IC | 13.4 | 13.3 | NA | NA | NA | NA | NA | NA |
| Richey et al., | 16 (14) | 19 (13) | 2 AS, 14 HFA (9 with psychotropic medication) | ADOS-G | 26 (9.1) | 25.3 (7) | NA | NA | NA | NA | NA | NA |
| Sasson et al., | 56 (35) | 213 (68) | ASD | AQ | 22.5 (5.08) | 21.4 (3.1) | NA | NA | NA | NA | NA | NA |
| Scott-Van Zeeland et al., | 16 (16) | 16 (16) | 6 ASD, 10 Autism (2 with psychostimulants, 2 atypical antipsychotics only, 3 both, 1 SSRI, 1 atypical antidepressant, 1 unknown) | ADOS and ADI-R | 12.4 (2.14) | 12.3 (1.76) | 112.3 (13.6) | 119 (8.4) | 108.8 (14.9) | 119.4 (12.6) | 114.1 (13.1) | 111.5 (8.1) |
| Sepeta et al., | 20 (NA) | 18 (NA) | Autism or AS | ADI-R or ADOS-G | 12.4 | 13.7 | 106 (20) | 117 (12) | 101 (20) | 117 (13) | 110 (18) | 112 (11) |
| Wilbarger et al., | 14 (11) | 14 (12) | AD or AS | ADI-R or ADOS-G | 21.9 (7.5) | 21.1 (5.7) | NA | NA | NA | NA | NA | NA |
AD, Autistic Disorder; ADI-R, Autism Diagnostic Interview-Revised; ADOS, Autism Diagnostic Observation Schedule; AS, Asperger's Syndrome; ASD, Autism Spectrum Disorder; AQ, Autism Quotient; DX, Diagnosis; FSIQ-4, Full-scale Intelligence Quotient with 4 subtests; HFA, High functioning Autism; IC, independent clinicians; NA, not available; PDD-NOS, Pervasive Developmental Disorder not otherwise specified; PIQ, Perceptual Intelligence Quotient; SD, Standard Deviation; VIQ, Verbal Intelligence Quotient.
Sepeta et al. (.
Participant characteristics of reviewed ASD studies in section Learning in the Context of Aversive Conditioning.
| Bernier et al., | 14 (12) | 14 (12) | AS, Autism or PDD-NOS | ADOS and ADI-R | 18.4 (5.5) | 19.7 (8.2) | 106.1 (13.0) | 114.9 (12.5) | NA | NA | NA | NA |
| Gaigg and Bowler, | 14 (12) | 14 (11) | AS (none) | IC | 29.7 (10.2) | 30.4 (12.2) | 111 (17.3) | 109 (12.7) | NA | NA | NA | NA |
| Salmond et al., | 14 (13) | 18 (6) | HFA or AS (none) | IC | 12.9 | 12.6 | NA | NA | 85-115 | 85-115 | NA | NA |
| Sears et al., | 11 (NA) | 11 (NA) | Autism | IC | 12.2 | 12.7 | NA | NA | NA | NA | 105.7 | 115.4 |
| South et al., | 36 (33) | 36 (32) | ASD | ADOS-G | 12.38 (2.69) | 13.18 (3.05) | 105.93 (11.89) | 109.43 (9.04) | 103.2 (13.90) | 108.4 (11.54) | 107.23 (12.77) | 108.13 (8.32) |
AD, Autistic Disorder; ADI-R, Autism Diagnostic Interview-Revised; ADOS, Autism Diagnostic Observation Schedule; AS, Asperger's Syndrome; ASD, Autism Spectrum Disorder; AQ, Autism Quotient; DX, Diagnosis; FSIQ-4, Full-scale Intelligence Quotient with 4 subtests; HFA, High functioning Autism; IC, independent clinicians; NA, not available; PDD-NOS, Pervasive Developmental Disorder not otherwise specified; PIQ, Perceptual Intelligence Quotient; SD, Standard Deviation; VIQ, Verbal Intelligence Quotient.
Sears et al. (.
Participant characteristics of reviewed ASD studies Learning and Decision-Making.
| D'Cruz et al., | 41 (33) | 37 (31) | 22 AD, 12 PDD-NOS, 7 AS (either medication naïve or free from medication for 5.5 half-lives of the drug) | ADOS and ADI-R | 15.34 (7.75) | 18.24 (8.12) | 103.9 (16.48) | 108.7 (11.97) | 102 (18.7) | 109 (12.59) | 104.73 (15.5) | 107.59 (12.55) |
| Faja et al., | 21 (16) | 21 (16) | ASD | ADOS and ADI-R | 82 (7.1) | 80.3 (7.6) | 104 (11.6) | 109.1 (7.2) | 107.1 (10.8) | 109 (9.5) | 99.1 (13) | 103.4 (8) |
| Harris et al., | 23 (22) | 19 (NA) | Autism | ADOS and ADI-R | 26 | 28 | >85 | NA | NA | NA | NA | NA |
| Johnson et al., | 15 (11) | 14 (10) | AD | ADI-R | 16.1 (2.3) | 15.9 (2.4) | NA | NA | NA | NA | NA | NA |
| Lin et al., | 10 (7) | 10 (7) | Autism or AS | ADOS and ADI-R | 28 (3.1) | 27 (3.1) | 113 (4.7) | 114 (13.4) | NA | NA | NA | NA |
| Mussey et al., | 18 (NA) | 15 (NA) | Autism | ADI-R | 19 (2.1) | 18.9 (3.3) | 94.8 (27.4) | 103.4 (17.2) | NA | NA | NA | NA |
| Schipul et al., | 18 (16) | 18 (17) | Autism | ADOS and ADI-R | 22.4 (9.6) | 22.4 (4.5) | 106.2 (11.9) | 111.2 (6.4) | 106.2 (14.9) | 110.1 (6.2) | NA | NA |
| Solomon et al., | 22 (18) | 25 (20) | 5 HFA, 16 AS, 1 PDD-NOS (no antipsychotic medication, abstained from psychotropic medication 48 h) | ADOS-G | 22.95 (5.11) | 23.36 (4.15) | 112.64 (12.44) | 114.17 (11.51) | 110.82 (13.07) | 112.54 (12.32) | 112.18 (12.94) | 112.04 (11.53) |
| South et al., | 48 (45) | 56 (42) | ASD | ADOS | 13.21 (2.27) | 12.57 (2.6) | 109.76 (13.36) | 113.82 (12.18) | NA | NA | NA | NA |
| Yechiam et al., | 15 (14) | 28 (26) | 12 AS, 2 PDD-NOS, 1 HFA | AQ and IC | 15.6 (2.8) | 15.6 (3.6) | NA | NA | NA | NA | NA | NA |
AD, Autistic Disorder; ADI-R, Autism Diagnostic Interview-Revised; ADOS, Autism Diagnostic Observation Schedule; AS, Asperger's Syndrome; ASD, Autism Spectrum Disorder; AQ, Autism Quotient; DX, Diagnosis; FSIQ-4, Full-scale Intelligence Quotient with 4 subtests; HFA, High functioning Autism; IC, independent clinicians; NA, not available; PDD-NOS, Pervasive Developmental Disorder not otherwise specified; PIQ, Perceptual Intelligence Quotient; SD, Standard Deviation; VIQ, Verbal Intelligence Quotient.
Mussey et al. (.